Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Terminated 1Recruiting 1Completed 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Endometrial Neoplasms 1

Interventions

Specimen Handling 480pembrolizumab 455Magnetic Resonance Spectroscopy 420Carboplatin 327Cyclophosphamide 314Cisplatin 271Biopsy 271Radiotherapy 244Paclitaxel 229Gemcitabine 227Bevacizumab 213Nivolumab 188fludarabine 185venetoclax 174Drug Therapy 170Blood Specimen Collection 158Dexamethasone 157Oxaliplatin 154Injections 152Capecitabine 151Fluorouracil 144Docetaxel 144Radiosurgery 137Standard of Care 135Rituximab 125Pemetrexed 117durvalumab 115Leucovorin 109atezolizumab 107Radiation 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × LY3023414 × 1 year × Clear all
NCT03675893 2025-06-15

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Dana-Farber Cancer Institute

Phase 2 Recruiting
180 enrolled
Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡